List of Elepsia Xr drug patents

Elepsia Xr is owned by Tripoint.

Elepsia Xr contains Levetiracetam.

Elepsia Xr has a total of 5 drug patents out of which 0 drug patents have expired.

Elepsia Xr was authorised for market use on 20 December, 2018.

Elepsia Xr is available in tablet, extended release;oral dosage forms.

The generics of Elepsia Xr are possible to be released after 31 October, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8535717 TRIPOINT Pharmaceutical composition
Feb, 2026

(2 years from now)

US8425938 TRIPOINT Pharmaceutical composition
Feb, 2026

(2 years from now)

US8163306 TRIPOINT Oral drug delivery system
Sep, 2027

(4 years from now)

US8431156 TRIPOINT Pharmaceutical composition
Oct, 2027

(4 years from now)

US8470367 TRIPOINT Oral drug delivery system
Oct, 2027

(4 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 20 December, 2018

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

ELEPSIA XR family patents

9

United States

5

India

2

Australia

2

Spain

2

Poland

2

Japan

2

European Union

1

Israel

1

South Africa

1

Denmark

1

Austria

1

Brazil

1

Portugal

1

Korea, Republic of

1

China

1

Ukraine

EA

1

EA

1

Canada

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in